Are patient questionnaire scores as "scientific" as laboratory tests for rheumatology clinical care?

Bulletin of the NYU Hospital for Joint Diseases

Volumn 68, Issue 2, 2010, Pages 130-139

  Pincus, Theodore ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; ARTICLE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEATH; DECISION MAKING; ERYTHROCYTE SEDIMENTATION RATE; GOLD STANDARD; HUMAN; LABORATORY TEST; PATIENT CARE; PHYSICAL EXAMINATION; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RADIOGRAPHY; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCORING SYSTEM; SURVIVAL TIME; WORK DISABILITY; DAILY LIFE ACTIVITY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISABILITY; PATIENT; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PSYCHOLOGY; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX;

ACTIVITIES OF DAILY LIVING; CLINICAL LABORATORY TECHNIQUES; DIAGNOSTIC TESTS, ROUTINE; DISABILITY EVALUATION; HUMANS; PATIENTS; PHYSICAL EXAMINATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUESTIONNAIRES; RHEUMATIC DISEASES; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 77954664636     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Peirce CS. The fixation of belief. Popular Science Monthly. 1877;12:1-15.
2. Dobson M. Nature of the urine in diabetes. Medical Observations and Inquiries. 1776;5:298-310.
3. Steinke J, Thorn GW. Diabetes mellitus. In: Wintrobe MM, Thorn GW, Adams RD, et al. (eds): Harrison's Principles of Internal Medicine (6th ed). New York: McGraw-Hill Book Co., 1970, pp. 523-539.
4. Banting FG, Best CH, Collip JB, et al. Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. Can Med Assoc J. 1922;12(3):141-6.
5. Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med. 1922;7:251-66.
6. Huisman TH, Martis EA, Dozy A. Chromatography of hemoglobin types on carboxymethylcellulose. J Lab Clin Med. 1958;52(2):312-27.
7. Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun. 1969;36(5):838-43.
8. Koenig RJ, Peterson CM, Jones RL, et al. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med. 1976;295(8):417-20.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
10. Rothschild BM. Diffuse idiopathic skeletal hyperostosis as reflected in the paleontologic record: dinosaurs and early mammals. Semin Arthritis Rheum. 1987;17:119-25.
11. Garrod AE. A Treatise on Rheumatism and Rheumatoid Arthritis. London: Charles Griffin & Co. Ltd., 1890.
12. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Path Microbiol Scand. 1940;17:172-8.
13. Rose HM, Ragan C, Pearce E, Lipman MO. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med. 1948;68:1-6.
14. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11dehydrocorticosterone; compound E) and of the pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin. 1949;24:181.
15. Hench PS. The potential reversibility of rheumatoid arthritis: heberden oration, Heberden Society of London, 15 October 1948. Mayo Clin Proc. 1949;24:167-78.
16. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis. 1995;54:944-7.
17. Weinblatt ME. Rheumatoid arthritis: treat now, not later! (Editorial). Ann Intern Med. 1996;124:773-4.
18. Sokka T, Pincus T. Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. Rheumatology (Oxford). 2008;47(10):1543-7.
19. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350:2167-79.
20. Schellekens GA, de Jong BAW, van den Hoogen FHJ, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101:273-81.
21. Riedemann JP, Muñoz S, Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis a systematic review. Clin Exp Rheumatol. 2005;23:S69-76.
22. Lipsky PE. Rheumatoid arthritis. In: Fauci AS, Langford CA (eds). Harrison's Rheumatology. New York: McGraw-Hill, 2006, pp. 85-104.
23. Chatham WW, Blackburn WD, Jr. Laboratory findings in rheumatoid arthritis. In: Koopman WJ, Moreland LW (eds). Arthritis and Allied Conditions: A Textbook of Rheumatology (15th ed). Philadelphia, PA: Lippincott, Williams & Wilkins, 2005, pp. 1207-1221.
24. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808.
25. Wolfe F, Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol. 1994;21:1227-37.
26. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol. 1997;24:1477-85.
27. Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol. 2009;36(7):1387-90.
28. Abelson B, Sokka T, Pincus T. Declines in erythrocyte sedimentation rates in patients with rheumatoid arthritis over the second half of the 20th century. J Rheumatol. 2009;36(8):1596-9.
29. Goldsmith CH, Smythe HA, Helewa A. Interpretation and power of pooled index. J Rheumatol. 1993;20:575-8.
30. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36:729-40.
31. Engel GL. The need for a new medical model: a challenge for biomedicine. Science. 1977;196:129-36.
32. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-45.
33. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis: the arthritis impact measurement scales. Arthritis Rheum. 1980;23:146-52.
34. Pincus T, Summey JA, Soraci SA Jr, et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum. 1983;26:1346-53.
35. Wolfe F. A brief health status instrument: CLINHAQ. (Abstract). Arthritis Rheum. 1989;32:S99.
36. Pincus T, Swearingen CJ. The HAQ compared with the MDHAQ: "keep it simple, stupid" (KISS), with feasibility and clinical value as primary criteria for patient questionnaires in usual clinical care. Rheum Dis Clin North Am. 2009;35(4):787-98
37. Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-72.
38. Kaplan HS. Survival as related to treatment. In: Kaplan HS (ed). Hodgkin's Disease. Cambridge: Harvard University Press, 1972, pp. 360-388.
39. Proudfit WL, Bruschke AVG, Sones FM Jr. Natural history of obstructive coronary artery disease: ten-year study of 601 nonsurgical cases. Prog Cardiovasc Dis. 1978;21:53-78.
40. Callahan LF, Pincus T, Huston JW, III, et al. Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years. Arthritis Care Res. 1997;10:381-94.
41. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S35-61.
42. Pincus T, Callahan LF, Vaughn WK. Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol. 1987;14:240-51.
43. Pincus T, Callahan LF, Brooks RH, et al. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med. 1989;110:259-66.
44. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med. 1994;120:26-34.
45. Pincus T, Keysor J, Sokka T, et al. Patient questionnaires and formal education level as prospective predictors of mortality over 10 years in 97% of 1416 patients with rheumatoid arthritis from 15 United States private practices. J Rheumatol. 2004;31:229-34.
46. Pincus T, Wolfe F. Patient questionnaires for clinical research and improved standard patient care: is it better to have 80% of the information in 100% of patients or 100% of the information in 5% of patients? J Rheumatol. 2005;32:575-7.
47. Pincus T. The DAS is the most specific measure, but a patient questionnaire is the most informative measure to assess rheumatoid arthritis. J Rheumatol. 2006;33:834-7.
48. Pincus T. Patient questionnaires and formal education as more significant prognostic markers than radiographs or laboratory tests for rheumatoid arthritis mortality--limitations of a biomedical model to predict long-term outcomes. Bull NYU Hosp Jt Dis. 2007;65(Suppl 1):S29-36.
49. Pincus T, Sokka T. Quantitative clinical rheumatology: "keep it simple, stupid": MDHAQ function, pain, global, and RAPID3 quantitative scores to improve and document the quality of rheumatologic care. J Rheumatol. 2009;36(6):1099-100.
50. Pincus T, Bergman MJ, Maclean R, Yazici Y. Complex measures and indices for clinical research compared with simple patient questionnaires to assess function, pain, and global estimates as rheumatology "vital signs" for usual clinical care. Rheum Dis Clin North Am. 2009;35(4):779-86.
51. Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum. 1999;42:1870-8.
52. Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum. 2000;43(3):506-14.
53. Wells G, Li T, Maxwell L, et al. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):260-5.
54. Pincus T, Amara I, Segurado OG, et al. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008;35(2):201-5.
55. Pincus T, Strand V, Koch G, et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the disease activity score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum. 2003;48(3):625-30.
56. Pincus T, Amara I, Koch GG. Continuous indices of Core Data Set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum. 2005;52:6.
57. Pincus T, Chung C, Segurado OG, et al. An index of patient self-reported outcomes (PRO Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006;33:2146-52.
58. Pincus T, Bergman MJ, Yazici Y, et al. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford). 2008;47(3):345-9.
59. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol. 2005;32:2410-5.
60. Pincus T, Yazici Y, Bergman M, et al. A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative Routine Assessment of Patient Index Data (RAPID) scores on a Multidimensional Health Assessment Questionnaire (MDHAQ). Best Pract Res Clin Rheumatol. 2007;21(4):789-804.
61. Hart LE, Tugwell P, Buchanan WW, et al. Grading of tenderness as a source of interrater error in the Ritchie articular index. J Rheumatol. 1985;12:716-7.
62. Lewis PA, O'Sullivan MM, Rumfeld WR, et al. Significant changes in Ritchie scores. Br J Rheumatol. 1988;27:32-6.
63. Klinkhoff AV, Bellamy N, Bombardier C, et al. An experiment in reducing interobserver variability of the examination for joint tenderness. J Rheumatol. 1988;15:492-4.
64. Thompson PW, Hart LE, Goldsmith CH, et al. Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. J Rheumatol. 1991;18:661-5.
65. Scott DL, Choy EHS, Greeves A, et al. Standardising joint assessment in rheumatoid arthritis. Clin Rheumatol. 1996;15:579-82.
66. Wakefield RJ, Kong KO, Conaghan PG, et al. The role of ultrasonography and magnetic resonance imaging in early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21:S42-9.
67. Pincus T, Swearingen CJ. Erythrocyte sedimentation rate (ESR) is the least likely of Core Data Set measures to identify an "abnormal state" in new patients with RA to monitor therapeutic responses, according to 3 definitions of "abnormal state." (Abstract #318). Arthritis Rheum. 2009;60(Suppl):S117.
68. Scott DL, Strand V. The effects of disease-modifying antirheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database. Rheum. 2002;41:899-909.
69. Cohen SB, Strand V, Aguilar D, Ofman JJ. Patientversus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. Rheumatology. 2004;43(6):704-11.
70. Olsen NJ, Callahan LF, Brooks RH, et al. Associations of HLA-DR4 with rheumatoid factor and radiographic severity in rheumatoid arthritis. Am J Med. 1988;84:257-64.
71. Pincus T, Sokka T. Quantitative measures to assess patients with rheumatic diseases: 2006 update. Rheum Dis Clin North Am. 2006;32(Suppl 1):29-36.
72. Pincus T, Askanase AD, Swearingen CJ. A multi-dimensional health assessment questionnaire (MDHAQ) and routine assessment of patient index data (RAPID3) scores are informative in patients with all rheumatic diseases. Rheum Dis Clin North Am. 2009;35(4):819-27.
73. Pincus T, Sokka T. Can a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores be informative in patients with all rheumatic diseases? Best Pract Res Clin Rheumatol. 2007;21(4):733-53.
74. Yazici Y, Bergman M, Pincus T. Time to score quantitative rheumatoid arthritis measures: 28-joint count, disease activity score, health assessment questionnaire (HAQ), multidimensional HAQ (MDHAQ), and routine assessment of patient index data (RAPID) scores. J Rheumatol. 2008;35:603-9.
75. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999;353:1568-73.
76. Puolakka K, Kautiainen H, Möttönen T, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. 2005;52(1):36-41.
77. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9.
78. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381-90.
79. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF. et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146(6):406-15.
80. Verstappen SMM, Jacobs JWG, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66(11):1443-9.
81. Hetland ML, Ejbjerg BJ, Horslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2 year randomised controlled trial (CIMESTRA). Ann Rheum Dis. 2009;68:384-90.
82. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis. 2008;67:815-22.
83. Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 2008;58(5):1310-7.